About
Guided by our values, we are an impact-driven organization that improves care in every setting – one product, one partner, one patient at a time.
Guided by our values, we are an impact-driven organization that improves care in every setting – one product, one partner, one patient at a time.
Through our core commitments, we are leveraging our scale for the greater good, such as serving the needs of our stakeholders, donating back to our communities, protecting our planet, working with policymakers, and more.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportOur businesses bring together leading technologies, innovative solutions and hands-on expertise to support the entire healthcare ecosystem.
We distribute pharmaceuticals and medical supplies to healthcare settings across North America, from pharmacies and hospitals to doctors’ offices and clinics.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
We provide research, insights, technologies and other support to help address challenges in cancer and specialty care.
We provide a suite of solutions designed to address access, affordability and adherence challenges by bridging the gaps between biopharma companies, pharmacies, providers, and payers to help patients get on and stay on their medications.
We offer solutions that enable employers, payers, health-plan brokers and government agencies to provide lower-cost options for prescription medications and therapies.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportCOVID-19 adds to testing burden, healthcare organizations to rethink standard strategies
Read time: 4.5 minutes
Respiratory season is a significant burden on the U.S. healthcare industry. Last year 26M+ flu cases were diagnosed,1 1.5M outpatient clinic visits among children under the age of five were attributed to Respiratory Syncytial Virus (RSV)2 and hospitals experienced 1.3M visits to emergency rooms (ER) to treat pneumonia.3
While experts hoped COVID-19 cases would drop with the arrival of warm summer weather similar to other respiratory illnesses, and some geographic regions have experienced a flatline or decrease in cases, other communities are experiencing a spike that is overwhelming local healthcare resources.
As healthcare organizations look toward the 2020-2021 respiratory season, they anticipate the unprecedented convergence of the typical respiratory illnesses: flu, pneumonia, bronchitis, RSV – with COVID-19 cases – and it is forcing them to reevaluate their approach to patient diagnosis, management and care.
The goal of testing is to provide rapid and accurate diagnosis, quickly get patients on the correct course of treatment, and in the case of easily transmitted viral illnesses, such as flu, help limit spread among the community.
"Speed and accuracy of COVID-19 testing is particularly important given its highly contagious nature and the significant risks it presents to vulnerable populations, but the demand is outpacing the supply for testing and PPE," said John Harris, VP, Strategic Accounts, Laboratory, McKesson. "Labs are performing hundreds of thousands of tests per day, which is placing a tremendous strain on the supply chain."
Active viral infection tests:
Antibody tests:
In order to implement a successful respiratory testing program that includes multiple test types (flu, RSV, Strep A and COVID-19), each individual healthcare entity should determine its own testing strategy that is aligned to its patients’ needs. This includes which tests to administer, where, when and how. Key areas for consideration:
The number one priority is to develop a holistic approach to testing. At the system level, a healthcare organization may evaluate testing options based on effectiveness, availability and cost.
An organization may consider its specific testing goals to evaluate whether a patient has potentially been exposed to a virus – whether it’s to quickly test and secure results at the point-of-care (POC) or to obtain accurate results through "swab and send" testing performed at a central lab.
"From a supply chain and cost perspective, an organization can turn to its distributor to understand current technologies on the market," said Harris. "With the on-set of COVID-19 there is a broad range of new diagnostics aimed at helping to address the pandemic."
"At McKesson, when we see opportunities or issues (e.g. promising new products, potential supply shortages), we inform our customers so they, in turn, can make the knowledgeable decisions for their organizations," said Harris.
While a healthcare organization should have an overarching testing strategy, that doesn’t mean it can apply a one-size fits all approach. Different care site categories manage different patient populations in different ways and therefore have different testing requirements. While decisions should be driven from the top to maintain strategic alignment, they’ll take into account the needs of front-line healthcare workers and their patients, which can vary by location.
Diversifying test options can help an organization address a broad range of requirements, protect staff and patients, and streamline the path to securing results. For example, it might decide that its physician offices perform rapid POC molecular testing for flu but adopt antigen testing for COVID-19 due to availability.
"The organization’s distributor can serve as a valuable resource, presenting practices from throughout the industry, and introducing testing options available and considerations for test supply management (e.g. proper storage, temperature)," said Harris.
Concerns and fears abound among healthcare providers and patients as we approach the upcoming respiratory season at the same time as COVID-19 cases surge in many markets. Now is the time for organizations to formulate their respiratory testing strategies with the understanding that past approaches to testing may not be effective in managing the unprecedented convergence of illnesses on the horizon.
A holistic approach to testing, that takes into account individual care site needs and is guided by industry knowledge supplied by distributors and other business relationships, will help organizations accurately diagnose respiratory patients and begin their course of care. While this has been important, this year it is critical to the well-being of our nation. The greater number of COVID-19 patients that clinicians can accurately diagnose, and the faster they can do so, the quicker these patients can isolate to help prevent further spread.
1Flu Season That's Sickened 26 Million May Be at Its Peak, U.S. News & World Report, February 21, 2020
2Respiratory Syncytial Virus-Associated Mortality (RSV-Associated Mortality) 2019 Case Definition, Centers for Disease Control and Prevention
3Fast Facts Pneumonia, Centers for Disease Control and Prevention
As oncology care becomes more complex, Ontada is exploring how an intelligent medical record could help community oncology practices connect data, reduce administrative burden and bring more actionable insights into everyday care.
While payer confidence in the science is growing, reimbursement complexity, data gaps and system misalignment remain barriers to broader cell and gene therapy access.
A 2026 survey of 100 senior-level life sciences professionals suggests the next opportunity in oncology real-world data is not simply more data, but linked data that is trusted, timely and ready to support stronger clinical and commercial decisions.
In a large U.S. community oncology cohort, use of GLP-1 receptor agonists was associated with improved overall survival, highlighting an important area for future research.
Community oncology is expanding access to advanced cancer care by bringing precision medicine, clinical research and technology-enabled support closer to where patients live and receive ongoing treatment.
McKesson supports healthcare providers and partners to improve access, strengthen local care, and help ensure medications reach patients in communities nationwide.
Explore how The US Oncology Network is shaping the future of community oncology through collaboration, innovation and partnership.
McKesson’s GPOs empower independent healthcare providers to access differentiated contract pricing and terms, navigate rising drug costs and sustain community-based care.
Leveraging data from the largest community oncology networks, we look at factors increasing colorectal cancer in younger patients.
How treatment centers can access CGTs through two different channel strategies — Buy-and-Bill and Specialty Pharmacy.